AU7370798A - Compositions and methods of therapy for igf-i-responsive conditions - Google Patents

Compositions and methods of therapy for igf-i-responsive conditions

Info

Publication number
AU7370798A
AU7370798A AU73707/98A AU7370798A AU7370798A AU 7370798 A AU7370798 A AU 7370798A AU 73707/98 A AU73707/98 A AU 73707/98A AU 7370798 A AU7370798 A AU 7370798A AU 7370798 A AU7370798 A AU 7370798A
Authority
AU
Australia
Prior art keywords
igf
therapy
gag
compositions
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73707/98A
Inventor
Alfredo Gorio
Eugenio E. Muller
Bruce F Scharschmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU7370798A publication Critical patent/AU7370798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions and methods useful in therapy for IGF-I-responsive conditions in a mammal are provided. The method comprises concurrent therapy with both IGF-I or a variant thereof and at least one GAG to promote a desired therapeutic response with respect to a particular IGF-I- responsive condition. Concurrent therapy is achieved by admininstering to a mammal a single pharmaceutical composition containing both IGF-I (or a variant thereof) and at least one GAG according to a dosing regimen. Alternatively, IGF-I or a variant thereof and at least one GAG can be administered as two separate pharmaceutical compositions. A pharmaceutical composition comprising IGF-I or a variant thereof and at least one GAG for use in the IGF-I and GAG therapy is also provided.
AU73707/98A 1997-05-06 1998-05-06 Compositions and methods of therapy for igf-i-responsive conditions Abandoned AU7370798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI97A1042 1997-05-06
IT97MI001042A IT1291307B1 (en) 1997-05-06 1997-05-06 PHARMACEUTICAL COMPOSITION SUITABLE FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES
PCT/US1998/009273 WO1998050062A1 (en) 1997-05-06 1998-05-06 Compositions and methods of therapy for igf-i-responsive conditions

Publications (1)

Publication Number Publication Date
AU7370798A true AU7370798A (en) 1998-11-27

Family

ID=11377071

Family Applications (1)

Application Number Title Priority Date Filing Date
AU73707/98A Abandoned AU7370798A (en) 1997-05-06 1998-05-06 Compositions and methods of therapy for igf-i-responsive conditions

Country Status (7)

Country Link
EP (1) EP1015019B1 (en)
JP (1) JP2002507193A (en)
AT (1) ATE293990T1 (en)
AU (1) AU7370798A (en)
DE (1) DE69829982T2 (en)
IT (1) IT1291307B1 (en)
WO (1) WO1998050062A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779532B2 (en) * 1999-07-21 2005-01-27 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0516901A1 (en) * 1991-06-06 1992-12-09 Richard L. Lindstrom Method and apparatus of a serumfree medical solution

Also Published As

Publication number Publication date
EP1015019A1 (en) 2000-07-05
ATE293990T1 (en) 2005-05-15
IT1291307B1 (en) 1999-01-07
DE69829982T2 (en) 2006-02-23
ITMI971042A0 (en) 1997-05-06
JP2002507193A (en) 2002-03-05
DE69829982D1 (en) 2005-08-18
ITMI971042A1 (en) 1998-11-06
WO1998050062A1 (en) 1998-11-12
EP1015019B1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
NZ502358A (en) Hydrogel composition comprising a biologically active substance combined with a macromer
PL319833A1 (en) Compounds and composition for carrying active media
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
ES2190472T3 (en) TRANSDERMIC PATCH FOR THE ADMINISTRATION OF 17-DEACETIL NORGESTIMATO, ONLY OR IN COMBINATION WITH A STROGEN.
DE69940674D1 (en) ORAL ADMINISTRATION OF ADENOSINE ANALOG
ZA921875B (en) New esters of bi- and tricyclic amino alcohols, their preparation and their use in pharmaceutical compositions
CA2170255A1 (en) Pharmaceutical Composition for Immunoenhancement Therapy
AU2084801A (en) Antiviral medication
DK0460062T3 (en) Huperzin A analogues
TW261615B (en)
DK1207870T3 (en) Pharmaceutical compositions containing N-palmitoylethanolamide and its use
TW200505436A (en) Modified release pharmaceutical compositions and the processes for preparing them
EP1093816A3 (en) Use of ST1435 in hormonal therapy by transdermal application
WO2003033678A3 (en) Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
EP1023901A4 (en) Ameliorant for hepatitis c remedial effect and application thereof
DE60103619D1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING ALGINATES
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
CA2361081A1 (en) Chaperonin 10 and .beta.-interferon therapy of multiple sclerosis
AU7439996A (en) Novel uses of mammalian ctla-8 and related reagents
EP1099439A3 (en) Use of apo B secretion/MTP inhibitors
WO2000061171A3 (en) Uses of mammalian ox2 protein and related reagents
ATE194498T1 (en) ANHYDROUS LACTULOSE-BASED AGENT
EP0190860A3 (en) 6-chloro-3-methyl-1h-2,3,4,5-tetrahydro-3-benzazepine-n-oxide and medical compositions using it

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase